Polycystic ovary syndrome (PCOS) affects 5%-10% of women in reproductive age, and it is the most common cause of infertility due to ovarian dysfunction and menstrual irregularity. Several studies have reported that insulin resistance is common in PCOS women, regardless of the body mass index. The importance of insulin resistance in PCOS is also suggested by the fact that insulin-sensitizing compounds have been proposed as putative treatments to solve the hyperinsulinemia-induced dysfunction of ovarian response to endogenous gonadotropins. Rescuing the ovarian response to endogenous gonadotropins reduces hyperandrogenemia and re-establishes menstrual cyclicity and ovulation, increasing the chance of a spontaneous pregnancy. Among the insulin-sensitizing compounds, there is myo-inosiol (MYO). Previous studies have demonstrated that MYO is capable of restoring spontaneous ovarian activity, and consequently fertility, in most patients with PCOS. With the present review, we aim to provide an overview on the clinical outcomes of the MYO use as a treatment to improve ovarian function and metabolic and hormonal parameters in women with PCOS.
Symptoms include: Irregular or irregular menstruation, Menorrhagia, Hirsutism, Acne, Pelvic Pain, Difficult to conceive, Acanthosis nigricans
Scientist Home Mixed Inositol
May be suitable for attention, conditioning:
Consumption:1 to 2 teaspoons each time after meal, to be taken once or twice a day. May dissolve the powder in water, juice or tea.
This product is a nutritional supplement and cannot replace medicine.
If there is any discomfort, it is recommended to stop taking it.
Use with caution for pregnant and lactating women.
If you do not understand the cause of the problem or the problem persists, please consult your doctor as soon as possible.
Main ingredients: Inositol, d-chiral inositol
Note: Some women may have Allergy to inositol, mild diarrhea without abdominal pain is normal. (don't go out within 1 hour after drinking)
Storage method: Please store in a cool and dry place.
Origin: Hong Kong, China
Ingredient: Inositol, D-chiro-inositol
Packaging: 150g per bottle.
1. Gerli S, Papaleo E, Ferrari A, et al. Randomized, double-blind, placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11:347-354
2. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev. Med Pharmacol Sci. 2009;13(2):105-110.
3. Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010;26(4):275-280.
5. M Minozzi,1 G D’Andrea,2 V Unfer2,31First Institute of Obstetrics and Gynecology, University La Sapienza; 2A.G.UN.CO. Obstetrics and Gynecology Centre, Rome, Italy. Treatment of hirsutism with myo-inositol: a prospective clinical study. RBMOnline - Vol 17 No 4. 2008 579-582 Reproductive BioMedicine Online; www.rbmonline.com/Article/3299 on web 20 August 2008.
6. Michele Pezza, Valentina Carlomagno, Ambulatorio di Dermatologia Casa di Cura Villa Maria Passo di Mirabella Eclano (AV), Italy. Inositol in women suffering from acne and PCOS: a randomized study . DOI: 10.15761/GOD.1000203
7. Renae C Fernandez,1,2,3 Vivienne M. Moore,1,3,4 Emer M Van Ryswyk,5 Tamara J Varcoe,1,2 Raymond J Rodgers,1,2 Wendy. A March,1,3 Lisa J Moran,1,6 Jodie C Avery,1,2 R Doug McEvoy,5,7 and Michael J. Davies1,2. Sleep disturbances in women with polycystic ovary syndrome: prevalence, pathophysiology, impact and management strategies. Journal List Nat Sci Sleep v.10; 2018 PMC5799701
This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.